Carteolol
- Level
- Commodity
- Parent
- 51263100
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51263106This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NF31401XG, chemically known as 2(1h)-quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro- but generally known as carteolol, which bears US NIH Compound Identifier 2583. Carteolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Carteolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06150MIG. The term CARTEOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules carteolol in its Anatomical Therapeutic Chemical (ATC) Classification. CARTEOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule carteolol under HS 29337900 and SITC 51561. As of Q4 2014, CARTEOLOL remains the US FDA Preferred Term for this commodity. Carteolol bears US NLM identifiers UMLS ID C0007299 and NCI Concept Code C65291. SMILES: O(CC(O)CNC(C)(C)C)C1C2CCC(=O)NC2CCC1.
Same parent
Under 51263100 · 75Activities that produce or sell this
KBLI · 8Inherited from family 51260000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.